Related Experiment Videos
[Calcium antagonists and treatment of chronic heart failure]
1Service de médecine interne et cardiologie, hôpital Avicenne, Bobigny.
Insights
Calcium antagonists offer dual benefits for heart failure treatment by improving systolic function and ventricular relaxation. Newer dihydropyridine generations show promise, addressing earlier controversies in heart failure management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure treatment has evolved through distinct stages based on disease pathophysiology.
- Key therapeutic strategies include diuretics, vasodilators, and ACE inhibitors.
Purpose of the Study:
- To analyze the role and evolving use of calcium antagonists in heart failure treatment.
- To evaluate clinical trials of second-generation dihydropyridine calcium antagonists.
Main Methods:
- Review of historical treatment approaches for heart failure.
- Analysis of clinical trial data for novel calcium antagonist molecules.
- Examination of drug effects on cardiac systolic function and ventricular relaxation.
Main Results:
- First-generation calcium antagonists yielded controversial results in heart failure.
- Newer dihydropyridine derivatives have been developed.
- Clinical trials are evaluating the efficacy of these advanced calcium antagonists.
Conclusions:
- Calcium antagonists present potential benefits for heart failure through vasodilation and improved relaxation.
- Second-generation dihydropyridines warrant further investigation for heart failure management.
Abstract:
The history of the treatment of heart failure may be divided into three stages, the consequences of different conceptions of the physiopathology of the disease, with diuretics to counteract salt and water retention, vasodilators to improve conditions of cardiac load, angiotensin converting enzyme inhibitors to limit the effect of neurotumoral and sympathetic activation. There are two main reasons for using calcium antagonist in heart failure, the first being arterial vasodilatation leading to improve systolic function and the second being the beneficial effect on ventricular relaxation. However, their use has been controversial because of the results obtained with the first generation of these drugs. New molecules derived from dihydropyridine have been developed. Clinical trials with these second generation calcium antagonists are analysed.